Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 49

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 49
---
     | Funding Contribution to  Bonus Pool |
| Revenue                       |     | $611M               |     | 0%            |     | 60%       |     | 0%                                  |
| Adjusted Free Cash Flow       |     | $41M                |     | 175%          |     | 20%       |     | 35%                                 |
| Strategic Business Objectives |     | 6 out of 9 Achieved |     | 75%           |     | 20%       |     | 15%                                 |
| Total                         |     |                     |     |               |     |           |     | 50%                                 |

#### Equity Awards
Equity awards serve two main purposes: (a) providing ongoing incentives tied to stockholder value, as reflected in the company’s stock price and (b) offering retention incentives through multi-year and performance-based vesting schedules. For our named executive officers, equity incentives constitute the majority of their compensation, aligning their interests with long-term company performance.

We grant annual equity awards under the 2019 Omnibus Incentive Plan, typically in the first quarter of each fiscal year. In March 2024, the equity awards for our named executive officers consisted of RSUs and PSUs. For the Chief Executive Officer, the target value was split equally between 50% RSUs and 50% PSUs. For the other NEOs, 75% of the target value was allocated to RSUs, and 25% to PSUs. These awards are designed to drive growth and enhance stockholder value as the stock price increases.

For the 2024 executive compensation program, based on shareholder feedback, the compensation committee structured the PSU program as follows:

| Metric              |     | Weighting |     | Details                                                                                                                                                                 |     | Vesting                                                                                                                                                   |
| 3-year Relative TSR |     | 50%       |     | Measurement Period:                                                                                                                                                     
 3-year performance measurement from 1/1/2024 to 12/31/2026; Use a calendar month averaging period for beginning (December 2023) and ending (December 2026) stock price. 
 Relative To:                                                                                                                                                            
 RUSSELL 3000 Medical Equipment and Services Sector Index, using a closed index approach.                                                                                |     | Shares earned at the end of the 3-year performance period, based on achievement against goal. If TSR is negative, only up to target (100%) may be earned. |
|